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Abstract 
Glioblastomas are the most frequent and 
malignant brain tumors in adults. Surgical 
cure is virtually impossible and despite of 
radiation and chemotherapy the clinical 
course is very poor. Epigenetic silencing of 
MGMT has been associated with a better 
response to temozolomide-chemotherapy. 
We previously showed that temozolomide 
increases the median survival time of 
patients with tumors harbouring deletions 
on 9p within the region for p15(INK4b), 
p16(INK4a), and 10q (MGMT).  
The aim of this study was to investigate 
the methylation status of p15, p16, 14ARF 
and MGMT in glioblastomas and to 
correlate the results with the clinical data. 
Only patients with KPS > 70, radical 
tumor resection, radiation and 
temozolomide-chemotherapy after 
recurrence were included.  
We observed promoter methylation of 
MGMT in 56% (15/27) and of p15 in 37% 
(10/27) of the tumors, whereas methylation 
of p16 and p14ARF were rare.  
Interestingly, methylation of p15 
emerged as a significant predictor of shorter 
overall survival (16.9 vs. 23.8 months, 
p=0.025), whereas MGMT promoter 
methylation had no significant effect on 
median overall survival under this 
treatment regimen (22.5 vs. 22.1 months, 
p=0.49). In the presence of other clinically 
relevant factors, p15 methylation remains 
the only significant predictor (p=0.021; 
Cox regression). 
Although these results need to be 
confirmed in larger series and under 
different treatment conditions, our 
retrospective study shows clear evidence 
that p15 methylation can act as an 
additional prognostic factor for survival and 
underlines that this tumor suppressor, 
involved in cell cycle control, can act as an 
attractive candidate for therapeutic 
approaches in glioblastomas.  
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Introduction 
Glioblastomas [World Health 
Organization (WHO) grade IV] are the 
most frequent and the most malignant 
brain tumors in adults. They arise either de 
novo without recognizable precursor 
lesions or develop from lower grade 
astrocytomas (secondary GBM). Despite of 
multimodal therapy approaches, the 
prognosis is generally poor but varies 
markedly between the malignancy grades 
and even between individuals with the same 








patients survive more than a year. (1) 
Besides radical surgery, a higher 
preoperative Karnofsky Performance Score 
(KPS) and younger age are predictors of a 
more favourable clinical course. (2-5) 
Over the past decades, genetic 
abnormalities involved in pathogenesis and 
progression of these tumors were 
identified. Several alterations were also 
shown to be correlated with prognosis.  
In novel studies progression-associated 
genetic markers in differing tumor entities 
as well as in gliomas are increasingly 
observed. Because of the mostly focal 
appearance of the changes to start with, the 
molecular-cytogenetic methods with their 
high dissolving ability are on this occasion 
essential. In a study which has just been 
finished, we compared the genetic 
aberration profile of the diffuse gliomas 
with the response rate of temozolomide 
chemotherapy. Because of the observation, 
we assume that there is minority of patients 
who survive for longer than 5 years after 
the recognition of a glioblastoma, surgery 
and a combined radio- and chemotherapy. 
We could show an until now unknown 
correlation of the patterns of genetic 
changes with the varying response rate of 
patients on this chemotherapy. Using CGH 
and LOH we could prove that gliomas 
patients with a tumor which shows a loss of 
9p or 10q significantly benefit from 
temozolomide treatment. The gene for the 
O (6) - methylguanine-methyltransferase 
(MGMT) is localised on chromosome 10 
(10q26) and encoded as the DNA repair-
enzyme O(6) -alkylguanine-DNA-
alkyltransferase (OGAT). The function of 
OGAT is the protection of the cells from 
alkylating substances by the removal of 
damaging DNA-methylisations i.e. for the 
demethylisation of methylguanine. The 
effect of the alkylating cytostaticum 
temozolomide is based exactly on these 
damaging DNA methylisations. The effect 
of the chemotherapeuticum is therefore 
impeded by MGMT and a loss of this 
would because of this be of advantage for 
the treated patients. Interesting for 
secondary studies is the question if the 
appropriate chromosomal regions on the 
apparently intact second chromosome 10 
are mutated, methylated or still active. 
Therefore the expression status and the 
methylisation pattern of MGMT in the 
post-characterised gliomas be analysed on a 
DNA-level. For that reason it should be 
clarified if the MGMT gene on the 
apparently intact chromosome 10 is still 
active of if it has been made inactive by the 
promotor-hypermethylisation and if a 
reduced dose of the gene will already be 
sufficient for therapeutic success. Current 
studies on anaplastic astrocytomas and 
glioblastomas have shown that patients with 
a promotor hypermethylisation of the 
MGMT gene benefit significantly from a 
nitrosoharn substance and temozolomide 
chemotherapy in comparison to patients 
whose tumors do not show any 
methylisation in the MGMT gene (27, 28). 
Deletion or mutation of the 
p16(INK4a)/ARF/p15(INK4b) locus on 
chromosome 9p21 is among the most 
common alterations seen in human cancer 
and in human gliomas. (6-9) The INK4a 
locus encodes two gene products that are 
involved in cell cycle regulation through 
inhibition of CDK4-mediated RB 
phosphorylation (p16) and binding to 
MDM2 leading to p53 stabilization 
(p14ARF). The tumor suppressor gene 
products p16 and p15 are both capable of 
binding to CDK4 and CDK6, these kinases 








binary complexes are responsible for 
phosphorylation of RB-protein at mid G1 
of the cell cycle. The phosphorylation of 
RB is assumed to be critical for progression 
through G1 and entry into S-phase of the 
cell cycle. Binding of INK4 to CDK4/6 
inhibits its kinase activity and thereby 
arrests progression through the cell cycle in 
mid-late G1. (10)  
Over half of the high grade gliomas lack 
a functional INK4a/ARF locus. Gliomas 
with intact INK4a/ARF carry mutations in 
other components of the RB and p53 
pathways implicating these two pathways as 
being absolutely critical in cell growth and 
death control. (11-14) Previous studies 
showed that deletion of 9p including the 
INK4a/b locus is a significant unfavorable 
prognostic factor for survival of 
glioblastoma patients. (15, 16) Further on, 
this alteration has been reported to be 
inversely correlated with the 
chemosensitivity of malignant gliomas. (17) 
Over the past years aberrant DNA 
methylation was shown to be a common 
molecular lesion in human tumors as well, 
which had also impact on patient prognosis 
and treatment response. Epigenetic 
silencing of p16 and p15 was shown in a 
variety of human neoplasms, in glioma 
patients hypermethylation is reported in 
about 30% of the cases. (18-21) Whereas in 
other tumors inactivation of both tumor 
suppressor genes was associated with 
prognosis and response to chemotherapy, a 
prognostic and predictive role in gliomas is 
not shown. (22-25)  
On the other hand, epigenetic silencing 
of the DNA repair gene O6-
methylguanine-DNA methyltransferase 
(MGMT) on chromosome 10q26 by 
hypermethylation has been linked to a 
better prognosis for glioblastoma patients 
treated with alkylating agents like 
temozolomide. (26-29) A benefit was not 
observed for patients with MGMT 
promoter methylation and BCNU-
chemotherapy. (30) Another study 
comparing different treatment regimens 
showed that the prognostic effect was only 
significant when patients were treated 
simultaneously with radio - and 
chemotherapy. (31) These results suggest 
that the reported impact of MGMT 
methylation is strongly dependent on 
therapeutic modalities and schedules. 
In our previous study we identified the 
negative prognostic impact for deletions on 
9p and 10q, which can be compensated by 
temozolomide treatment. (16) In the 
current setting, our aim was to investigate 
the methylation status of p15, p16, p14ARF 
and MGMT, and correlate the results with 
the clinical data of the glioblastoma 
patients. 
Materials and Methods 
Patients and tumor samples 
The retrospective study included 27 
glioblastoma patients (23 primary and 4 
secondary GBM) who underwent surgery 
at the Department of Neurosurgery of the 
Saarland University, Homburg, Germany. 
After radical tumor surgery, all patients 
received standard radiation therapy (RT) 
(1.8-2 Gy, total dose of 60 Gy) and adjuvant 
temozolomide chemotherapy in case of 
recurrence. The doses were 150 mg/m² for 
5 days in 4 week cycles. Specimens of 
resected tumor were immediately shock 
frozen in liquid nitrogen and stored at –
80°C or fixed in formalin and embedded in 
paraffin. All patients gave written informed 
consent for the use of the tumor samples 








Methylation-specific polymerase chain 
reaction (MS-PCR) 
DNA of the tumor samples was isolated 
following standard protocols with 
chloroforme followed by sodium bisulfite 
modification. Promoter hypermethylation 
of the MGMT, p15, p16 and p14ARF genes 
were determined by MS-PCR as described 
previously. (18, 26, 32) The amplified 
products were electrophoresed on 3.5% 
agarose gels and visualized with ethidium 
bromide. Methylated blood DNA was 
included in each PCR set as methylated and 
unmethylated controls, respectively.  
Statistical analyses 
Comparison of survival times between  
groups defined by methylation status was 
performed by Kaplan-Meier curves and 
with two-sided log rank tests. Multivariate 
Cox regression analysis was performed to 
identify significant predictors for survival. 
Effects in these models were quantified by 
hazard ratio estimates with 95% confidence 
intervals. Median survival rates were 
calculated using the Kaplan-Meier method. 
Results  
Clinical Data  
Median age at surgery was 49 years 
(range 26-70), the sex ratio was 2.375 (19 
men / 8 women) (Table 1) and median post 
operative KPS was 100 (range 80-100, 18 
patients with KPS 100). 
 
Case Histologic age/ ST MGMT- p15- p16- p14ARF- 
 type sex [months] status status status status 
         
T4789 GBM 38/m 55,3 M U U U 
596/98 GBM 32/m 21,1 U U U U 
1099/98 GBM 49/m 23,8 U U U U 
1782/98 sGBM 26/m 24,2 M U U U 
896/99 GBM 51/m 13 U M U U 
1326/99 GBM 56/m 19,2 U U U U 
1349/99 GBM 54/m 72,6 M U U U 
1460/99 GBM 31/f 11,9 M M U U 
1795/99 sGBM 31/m 6,9 M U U U 
265/00 GBM 46/f 23,1 U M n.a.  U 
497/00 GBM 58/f 16,9 M  M U U 
1106/00 GBM 70/m 19,8 M M U U 
1691/00 sGBM 39/f 80,2 M U U U 
1707/00 GBM 47/m 29,4 U U U U 
643/01 GBM 54/f 26,6 U  U U U 
662/01 GBM 70/m 13,4 U M U U 
1405/01 GBM 53/m 7,4 U M M U 
6/02 GBM 41/m 26,2 M U U U 
369/02 sGBM 37/m 20,2 M U U U 
947/02 GBM 46/m 17,7 M M U U 
1536/02 GBM 53/m 15,1 U U U U 
1940/02 GBM 54/f 14,3 M M U U 








316/03 GBM 63/f 23,7 U U n.a.  U 
784/03 GBM 52/m 22,5 M  U U U 
831/03 GBM 58/m 53 U U n.a.  U 
1457/03 GBM 37/m 49,1 M M n.a.  U 
 
Methylation analyses 
The MGMT promoter was methylated 
in 15/27 cases (55.6%), the p15 promoter 
was methylated in 10/27 (37%) 
glioblastomas. All secondary GBM (4/4) 
showed a methylated MGMT promoter 
and an unmethylated p15 promoter. 
Methylation of p14ARF was absent in all 
(27/27) investigated GBM. Methylation 
status of p16 was available for 23/27 
glioblastomas. Hypermethylation of p16 
was detected in only 1/23 cases (4.3%) 
(Table 1). 
Clinical outcome 
Overall median survival was 22.5 
months with a two-year survival rate of 
35.0%.  
In univariate analyses, MGMT 
methylation had no impact on overall 
survival (22.5 vs. 22.1 months, p=0.49, log-
rank test, Fig. 1A), whereas p15 methylation 
was associated significantly with a shorter 
overall survival (16.9 vs. 23.8 months; 
p=0.0252, log-rank test, Figure 1B). Table 
2 contains estimated hazard ratios and p-
values for univariate analyses for all 
examined variables. 
We also performed a multivariate 
analysis including parameters previously 
identified as significant. As shown in Table 
3, only p15 methylation emerged as a 
significant prognostic factor after adjusting 
for KPS, sex, age and MGMT. In the first 
analysis, the predictors KPS and age enter as 
numerical variables in the model, in the 
second analysis KPS and age are 
dichotomized with cutoffs 90 and 50 in 
order to reduce model complexity. The 
gender variable sex is set to 1 for females 
and 0 for males. Both analyses yield very 
similar results, identifying p15 methylation 
as only significant predictor. 
Discussion 
A better understanding of the genetic 
alterations predicting disease outcome and 
therapy response in patients with high grade 
gliomas will help to optimize both 
treatment and overall outcome. In our 
study setting, MGMT promoter 
methylation had no significant impact on 
survival, in contrast with other studies that 
observed a strong effect on patient response 
and on survival in larger cohorts treated 
with radio- and temozolomide-
chemotherapy. (26, 28) This discrepancy 
might result, besides our smaller patient 
cohort, from the different treatment 
schedules. Actually, comparing various 
treatment modalities in glioblastomas, the 
prognostic effect of MGMT methylation 
was observed only when simultaneous 
chemoirradiation was administered. (26, 31)  
Further on, our PCR-results showed 
besides the methylated band also 
unmethylated bands in a large number of 
tumors. Taking into account this 
heterogeneity and that we are dealing with 
diffusely growing gliomas, (33, 34) this 
observation arises most likely from a 
different tumor cell population and from 
normal cells contaminating the tumor 
sample. Nevertheless, this heterogeneous 
methylation pattern may also result in 
different amounts of MGMT and therefore 








All evidence collected to date implicates 
that the INK4a/ARF gene products are 
critically important in control of growth 
arrest and senescence. Loss of p16 and ARF 
expression is associated with many human 
cancers, particularly gliomas. (20) A 
number of studies have shown that 
reconstitution of INK4a/ARF expression in 
glioma cells altered growth characteristics, 
reduced tumorigenicity and decreased 
invasive potential. These studies 
demonstrate the importance of the 
INK4a/ARF pathway in suppression of the 
neoplastic phenotype and suggest that 
restoration of a functional INK4a/ARF 
locus will be an important means of 
controlling the growth of gliomas. (36, 37)  
A striking observation of our study is the 
significant correlation of p15 methylation 
with a poorer clinical course. Loss of p15 
had not been widely investigated previously 
as a potential determinant of chemo- and 
radiosensitivity or as a prognostic factor. To 
our knowledge, this is the first study 
showing inactivation of p15 by promoter 
hypermethylation to be a predictor for an 
unfavorable clinical course. Cyclin 
dependent kinase inhibitors (p16, p21, p27) 
were shown to exhibit an antitumor effect 
in malignant gliomas inducing growth 
arrest and apoptosis in cell culture. (36, 37) 
Further on, retrovirus mediated transfer of 
INK4a halts glioma formation in a rat 
model. (38) This corroborates the idea that 
retrovirus mediated gene transfer of 
INK4a/b may also be an effective means to 
arrest human gliomas. Therefore, restoring 
the normal function of p15 by gene therapy 
is an attractive goal in the treatment of 
human gliomas. 
Furthermore, our finding that 
glioblastomas have not simultaneously 
hypermethylated the investigated tumor 
suppressor genes on 9p implicates that these 
tumors carry no general defect in their 
pattern of CpG island methylation. 
Interestingly, all secondary GBM (4/4) 
showed a methylated MGMT promoter 
and an unmethylated p15 promoter which 
indicates that distinct molecular pathways 
constitute for primary and for secondary 
glioblastomas and let them differ both in 
biological behavior and in clinical outcome. 
This corresponds to the finding that 
methylation of p14ARF is associated with a 
shorter patient survival and is mutually 
exclusive of MGMT promoter methylation 
except of one case in low grade astrocytoma 
who underwent progression or recurrence. 
(35) In our patient cohort that mainly 
consists of primary glioblastoma, p14ARF 
was not observed, supporting that this 
alteration is mainly restricted to secondary 
glioblastoma and therefore in the pathway 
of astrocytoma progression. 
Although these results need to be 
confirmed in larger series, our retrospective 
study suggests that p15 hypermethylation 
can act as an additional important 
prognostic factor for survival in 
glioblastomas. Further investigations have 
to clarify if p15 methylation is a predictive 
factor for temozolomide treatment response 
and can act as a prognostic parameter for 
survival, independent of therapy. 
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